Multidisciplinary and Comprehensive Chinese Medicine for Advanced Non-Small Cell Lung Cancer Patient

来源 :中国结合医学杂志(英文版) | 被引量 : 0次 | 上传用户:huanan_0909
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
Objective:To investigate the effects of multidisciplinary and comprehensive Chinese medicine (CM)treatments on progression-free survival (PFS) and median survival time (MST) in patients with advanced non-small cell lung cancer (NSCLC) and identify factors that influence progression and prognosis.Methods:Clinical data of 855 patients with advanced NSCLC who received multidisciplinary and comprehensive CM treatments at Longhua Hospital from January 2009 to December 2018 were retrospectively analyzed.Univariate analysis was performed by the Kaplan-Meier method and log-rank sequential inspection.Multivariate analysis of significant variables from the univariate analysis was performed with Cox regression modeling.Key factors correlated to progression and prognosis were screened out,and a Cox proportional hazard model was established to calculate the prognostic index.Results:The PFS and MST of 855 advanced NSCLC patients were 9.0 and 26.0 months,respectively.The 1-,2-,3-,and 5-year survival rates were 79.2%,54%,36.2%,and 17.1%,respectively.Gender,pathologic type,and clinical stage were independent prognostic risk factors;surgical history,radiotherapy,treatment course of Chinese patent medicine,intravenous drip of Chinese herbal preparation,duration of oral administration of Chinese herbal decoction (CHD),and intervention measures were independent prognostic protective factors.Gender was an independent risk factor for progression,while operation history and oral CHD administration duration were independent protective factors (all P<0.05).Women with stage Ⅲb-Ⅲc lung adenocarcinoma had the best outcomes.Conclusions:Female patients have lower progression risk and better prognoses than male patients,younger patients have higher progression risk but better long-term prognoses than the elderlys,and patients with lower performance status scores are at lower risk for progression and have better prognoses.Comprehensive CM treatments could significantly reduce progression risk,improve prognosis,and prolong survival time for patients with advanced NSCLC.This treatment mode offers additional advantages over supportive care alone.
其他文献
Objective:To investigate the effect of Kangquan Recipe(康泉方,KQR) on bone morphogenetic protein and activin membrane-bound inhibitor (BAMBI) expression and its mechanism in rats with benign prostatic hyperplasia (BPH).Methods:Forty-eight male Sprague-Dawley
Objective:To investigate the evolution of herbal medicine in treating tuberculosis (TB) and encourage anti-TB drug discovery and development.Methods:In this study,477 ancient traditional Chinese medicine formulae were collected from the Dictionary of Trad
目的 应用足三里穴位注射黄芪注射液治疗机械通气的重症肺炎患者,观察该疗法对脱机时间的影响及膈肌收缩功能的干预效果.方法 将患者60例随机分为治疗组与对照组各30例.对照组采取常规对症治疗,治疗组在此基础上加用足三里穴位注射黄芪注射液.观察两组患者有创机械通气时间、治疗14 d脱机率、治疗前后膈肌增厚率(DTF)、氧合指数(OI).结果 治疗组有创机械通气时间短于对照组,差异有统计学意义(P<0.05);治疗14 d后,治疗组脱机率为86.67%,对照组脱机率为76.67%,治疗组优于对照组,但差异无统计学
目的 观察探讨人参皂苷Rh2对大鼠心肌缺血再灌注损伤中NLRP3、白细胞介素-1β(IL-1β)、肿瘤坏死因子-α(TNF-α)水平及SOD活性的影响.方法 将40只SD大鼠随机分为4组,每组10只,即对照组、模型组、人参皂苷Rh2低剂量组(10 mg/kg)、人参皂苷Rh2高剂量组(20 mg/kg).人参皂苷组于模型制备前10 d开始连续灌胃给药,每天给药1次,对照组和模型组给予等体积的二甲基亚砜(DMSO)灌胃.通过结扎大鼠左冠状动脉前降支0.5 h再灌注4 h建立大鼠心肌缺血再灌注损伤模型.再灌注
笔者运用“邪伏膜原”理论辨治急性脑膜感染,认为膜原有“形而下”及“形而上”两种含义,脑膜当归属膜原.本团队主张感受外邪伏居膜原是引起脑膜感染的前提,发病后表现出“速传三焦,多脏同病”的特点,并将病程分为早期、中期、后期、恢复期4个阶段,依次呈现出“热、湿、瘀、虚”的病机变化特点.在治疗上提出早期开达膜原,清热熄风,通经止痛,方以达原饮、羚角钩藤汤、芎芷石膏汤合用,临证加减;中期清热化湿,解毒祛浊,方以甘露消毒丹、柴芩温胆汤为主;后期清营养阴,活血通络,方以清营汤为代表;恢复期清润养阴,甘平益气,方以沙参麦
目的 观察冲击波配合颈舒颗粒治疗神经根型颈椎病(气滞血瘀证)的临床效果.方法 69例患者随机分为3组各23例.药物组采用口服颈舒颗粒疗法治疗,冲击波组采用冲击波疗法治疗,治疗组采用冲击波配合口服颈舒颗粒进行治疗,疗程为8周.记录停药后、停药后1个月、停药后3个月的颈椎病临床评价量表(CASCS)、田中靖久颈椎病量表评分及视觉模拟量表(VAS)评分.结果 各组停药后、停药后1个月、停药后3个月CASCS评分、田中靖久颈椎病量表评分均较治疗前升高(P<0.05),VAS评分均较治疗前降低(P<0.05);治疗
Objective:To investigate the effects of emodin on inflammation and autophagy in lipopolysaccharide (LPS)-induced RAW 264.7 macrophages and reveal its underlying mechanism.Methods:3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H
Objective:Using network pharmacology to explore the mechanism of the \'invigorating qi and promoting blood circulation\'drug pair Ginseng-Danshen (Salvia miltiorrhiza) on treatment of ischemic heart disease (IHD).Methods:The chemical constituents of g
目的 观察生脉汤合血府逐瘀汤对保守治疗非ST段抬高型心肌梗死(NSTEMI)患者生物标志物的影响.方法 连续性纳入本院行保守治疗的80例NSTEMI患者,按照整群随机化法分为对照组与观察组各40例.对照组患者给予指南推荐的西医治疗方案,观察组患者在西医治疗方案的基础上加用生脉汤合血府逐瘀汤,两组均连续治疗14 d.于治疗前后,检测两组患者的超敏C反应蛋白(hs-CRP)、降钙素原(PCT)、N末端B型利钠肽原(NT-proBNP)、纤维蛋白原(FIB)及D-二聚体水平,观察主要心血管不良事件(MACE).
Objective:To investigate whether ginsenoside Rb1 (Rb1) can protect human umbilical vein endothelial cells (HUVECs) against high glucose-induced apoptosis and examine the underlying mechanism.Methods:HUVECs were divided into 5 groups:control group (5.5 mmo